Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Alector Inc. (ALEC) Insider Trading Activity
Healthcare • Biotechnology • 245 employees
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Total Value
-$419,579.61
Total Shares
1,097,427
Average Trade Value
-$34,964.97
Most Active Insider
Rosenthal Arnon
Total Activity: $200,618
Largest Single Transaction
$131,442
by Rosenthal Arnon on Dec 2, 2024
30-Day Activity
4 Transactions
Volume: 103,800 shares
Value: $152,312
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
President and Head of Rd
|
Mar 3, 2025 | 29,073 | $42,662 | 536,142 (-5.4%) | Sale | |
|
Chief Financial Officer
|
Mar 3, 2025 | 18,091 | $26,547 | 312,560 (-5.8%) | Sale | |
|
Chief Executive Officer
|
Mar 3, 2025 | 40,330 | $59,176 | 2,466,744 (-1.6%) | Sale | |
|
Chief Medical Officer
|
Mar 3, 2025 | 16,306 | $23,927 | 332,977 (-4.9%) | Sale | |
|
Chief Financial Officer
|
Dec 2, 2024 | 16,489 | $41,542 | 330,651 (-5.0%) | Sale | |
|
Chief Executive Officer
|
Dec 2, 2024 | 52,172 | $131,442 | 2,507,074 (-2.1%) | Sale | |
|
Chief Medical Officer
|
Dec 2, 2024 | 14,892 | $37,519 | 349,283 (-4.3%) | Sale | |
|
President and Head of Rd
|
Dec 2, 2024 | 26,500 | $66,764 | 565,215 (-4.7%) | Sale | |
|
Chief Financial Officer
|
Oct 1, 2024 | 216,400 | $0 | 347,140 (+62.3%) | Grant | |
|
President and Head of Rd
|
Oct 1, 2024 | 300,000 | $0 | 591,715 (+50.7%) | Grant | |
|
Chief Medical Officer
|
Oct 1, 2024 | 184,380 | $0 | 364,175 (+50.6%) | Grant | |
|
Chief Executive Officer
|
Oct 1, 2024 | 610,500 | $10,000 | 2,559,246 (+23.9%) | Grant |